References

The use of MR contrast in nonneoplastic disease of the brain.

10.1097/00002142-199500730-00004 · 1995 · External reference

Clinical safety of gadoteridol, representative of the macrocyclic class of gadolinium-based contrast agents.

10.1002/jmri.26957 · 2020 · External reference

Basic MR relaxation mechanisms and contrast agent design.

10.1002/jmri.24787 · 2015 · External reference

Design of gadoteridol-loaded cationic liposomal adjuvant CAF01 for MRI of lung deposition of intrapulmonary administered particles.

10.1021/acs.molpharmaceut.9b00908 · 2019 · External reference

Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.

10.2214/ajr.10.5992 · 2011 · External reference

Quantitatively relating magnetic resonance T(1) and T(2) to glycosaminoglycan and collagen concentrations mediated by penetrated contrast agents and biomacromolecule-bound water.

10.1093/rb/rbad035 · 2023 · External reference

Prospective imaging trial assessing gadoteridol retention in the deep brain nuclei of women undergoing breast MRI.

10.1016/j.acra.2020.01.007 · 2020 · External reference

Gadolinium-based contrast agent biodistribution and speciation in rats.

10.1148/radiol.230984 · 2023 · External reference

Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-Associated reports in the FDA Adverse Event Reporting System (FAERS).

10.1016/j.jaip.2020.09.021 · 2021 · External reference

The medical dictionary for regulatory activities (MedDRA).

10.2165/00002018-199920020-00002 · 1999 · External reference

Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.

10.1038/s41598-024-67209-0 · 2024 · External reference

The reporting odds ratio and its advantages over the proportional reporting ratio.

10.1002/pds.1001 · 2004 · External reference

Data mining of the public version of the FDA adverse event reporting system.

10.7150/ijms.6048 · 2013 · External reference

Adverse events related to off-label drugs using spontaneous adverse event reporting systems.

10.2147/tcrm.s321789 · 2021 · External reference

Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.

10.1016/j.jep.2024.119010 · 2025 · External reference

Modified generalized Weibull distribution: theory and applications.

10.1038/s41598-023-38942-9 · 2023 · External reference

Parametric regression model for survival data: Weibull regression model as an example.

10.21037/atm.2016.08.45 · 2016 · External reference

Recent developments and future perspectives in magnetic resonance imaging and computed tomography contrast media.

10.1097/rli.0000000000001180 · 2026 · External reference

Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.

10.1016/j.neurad.2020.05.008 · 2020 · External reference

Contrast-enhanced cardiac magnetic resonance imaging with a manganese-based alternative to gadolinium for tissue characterization of acute myocardial infarction.

10.1161/jaha.122.026923 · 2023 · External reference

Clinical safety of gadobutrol: review of over 25 years of use exceeding 100 million administrations.

10.1097/rli.0000000000001072 · 2024 · External reference

Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting system.

10.1007/s00415-025-13172-3 · 2025 · External reference

Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.

10.1186/s12916-024-03537-2 · 2024 · External reference

The reporting frequency of skin lesions in contrast media-induced chemical hypersensitivity.

2019 · External reference

Assessment of first-time and repeated acute adverse reactions to gadolinium-based contrast agents in MRI: a retrospective study.

10.1016/j.ejrad.2024.111504 · 2024 · External reference

Relationship between patient-friendly audiovisual systems and MRI contrast agent to adverse reactions.

10.1002/jmri.28951 · 2024 · External reference

Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis.

10.1001/jamainternmed.2019.5284 · 2020 · External reference

A mast-cell-specific receptor mediates Iopamidol induced immediate IgE-independent anaphylactoid reactions.

10.1016/j.intimp.2019.105800 · 2019 · External reference

MRGPRX2 mediates immediate-type pseudo-allergic reactions induced by iodine-containing iohexol.

10.1016/j.biopha.2021.111323 · 2021 · External reference

Inhibitory effect of daphnetin on the C48/80-induced pseudo-allergic reaction.

10.1016/j.intimp.2023.110874 · 2023 · External reference

Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.

2014 · External reference

Road less traveled: drug hypersensitivity to fluoroquinolones, vancomycin, tetracyclines, and macrolides.

10.1007/s12016-021-08919-5 · 2022 · External reference

Anti-pseudo-allergy effect of isoliquiritigenin is MRGPRX2-dependent.

10.1016/j.imlet.2018.04.004 · 2018 · External reference

Auricular vagal nerve stimulation inhibited central nerve growth factor/tropomyosin receptor kinase A/Phospholipase C-Gamma signaling pathway in functional dyspepsia model rats with gastric hypersensitivity.

10.1016/j.neurom.2023.01.007 · 2024 · External reference

Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?

10.1177/02841851211034038 · 2022 · External reference

Navigating nephrotoxic waters: a comprehensive overview of contrast-induced acute kidney injury prevention.

10.4329/wjr.v16.i6.168 · 2024 · External reference

Preventing allergic reactions to gadolinium-based contrast agents.

10.1097/rmr.0000000000000106 · 2016 · External reference

Sexual dimorphism in drug metabolism and pharmacokinetics.

10.2174/1389200220666191021094906 · 2019 · External reference

Sex hormones and epigenetic dysregulation in autoimmune disease.

10.1016/j.coi.2025.102595 · 2025 · External reference